This episode focuses on “multi-metabolic medicine,” including a roundtable whose guests run multi-metabolic practices in the US and Spain and an interview with Dr. Emily Andaya, an advocate for including the liver in the American Heart Associations’s CKM initiative.
This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent studies discussing patient genotyping and clustering.
A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
This conversation includes two separate themes: the rationale and impact around the price of resmetirom, and the impact of GLP-1s on resmetirom use in patients with MASH.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
Zobair Younossi and the Surfers, including Global NASH Council member Jörn Schattenberg, discuss Zobair’s work through the Global NASH Council and some implications for low SDI vs. high SDI countries.
Zobair Younossi and Louise Campbell lead a discussion that focuses first on slowing the growth of the MASLD pandemic, then on issues specific to menopausal women
Zobair Younossi joins the Surfers to discuss cost and cost effectiveness, including both how it is measured and how stakeholders might think about it, in the context of the MASLD disease burden.
